• Taltirelin Acetate: Practical PD Assay Workflows

  2026-09-23

  Taltirelin acetate offers a practical way to test neuroprotection across toxin-based Parkinson’s disease models, with evidence spanning cell survival, oxidative stress, and pathological protein cleavage. This guide turns those findings into an assay workflow while distinguishing established PD results from separate itch, sleep, and formulation research applications.

• AEBSF.HCl Workflows for Protease Mechanism Studies

  2026-09-23

  AEBSF.HCl gives researchers an irreversible, broad-spectrum serine protease perturbation tool for enzyme, cell-lysis, APP-processing, and regulated cell-death workflows. Its greatest value in MLKL-necroptosis experiments is as a mechanistic comparator that helps separate serine-protease effects from lysosomal cathepsin-driven injury.

• Vancomycin C6417 for Reliable Cell Assays

  2026-09-22

  Learn how Vancomycin SKU C6417 can support controlled antibacterial perturbation studies while reducing ambiguity in cell viability and cytotoxicity workflows. The article connects mechanism, solvent handling, assay controls, microbiome evidence, and vendor-selection criteria for reproducible laboratory decisions.

• FPS-ZM1 and the Next RAGE Research Frontier

  2026-09-22

  A translational analysis of FPS-ZM1 as a selective RAGE inhibitor, connecting amyloid beta signaling and neuroinflammation with emerging RAGE/POMC findings in metabolic disease while defining practical validation steps and research limitations.

• PS Nanoplastics and Cadmium: IP3R/Ca2+/STAT3

  2026-09-21

  The 2026 Toxicology study links polystyrene nanoplastic and cadmium co-exposure to intestinal apoptosis through an IP3R/Ca2+/STAT3 signaling axis. By combining C. elegans and Caco-2 models with pharmacological inhibition and Ca2+ chelation, the work provides mechanistic evidence relevant to environmental toxicology and calcium signaling modulation.

• Midecamycin In Vitro Activity: Findings from 1983

  2026-09-21

  Harold C. Neu’s 1983 study systematically mapped the in vitro activity of midecamycin across clinically derived gram-positive and gram-negative isolates. The findings established useful activity against many streptococci, staphylococci, Haemophilus influenzae, and Listeria, while showing lower potency than erythromycin and no reliable activity against erythromycin-resistant organisms.

• Taltirelin Acetate: Applied Research Workflows

  2026-09-20

  Taltirelin acetate connects TRHR1 pharmacology with practical itch, neuroprotection, formulation, and sleep-related research workflows. This guide translates mouse evidence into executable assay design, dosing decisions, controls, and troubleshooting steps while separating established findings from exploratory applications.

• Amphotericin B: Assay Design Beyond Membrane Lysis

  2026-09-19

  Amphotericin B is a polyene antifungal antibiotic whose membrane activity can be separated from immune and cytotoxic effects through layered assay design. This guide combines sterol biology, cytokine profiling, and lessons from a canine epithelial-cell study to improve fungal infection research reproducibility.

• EPZ-6438: Precision EZH2 Inhibitor Workflows

  2026-09-18

  EPZ-6438 gives researchers a selective chemical handle for connecting EZH2 activity with H3K27me3 loss, transcriptional change, and cancer-cell phenotypes. This guide translates that mechanism into practical workflows for EZH2-mutant lymphoma, malignant rhabdoid tumor models, and combination studies in treatment-resistant melanoma.

• FPS-ZM1 RAGE Inhibitor: Assay Workflow

  2026-09-18

  Use FPS-ZM1 to isolate RAGE-dependent effects in amyloid, hypothalamic, and neuroinflammation experiments. This practical workflow emphasizes solvent control, receptor confirmation, pathway-specific readouts, and careful interpretation of findings from berberine-based metabolic studies.

• Bufuralol Hydrochloride in Translational Assays

  2026-09-17

  Bufuralol hydrochloride is a non-selective β-adrenergic receptor antagonist suited to mechanistic cardiovascular pharmacology research. This article presents a decision framework for pairing its established pharmacology with human iPSC-derived intestinal organoids without overstating what the model can prove.

• Methoxy-X04 for Microglial Plaque Clearance

  2026-09-17

  Methoxy-X04 is a brain-permeable fluorescent amyloid beta probe for connecting plaque imaging with microglial clearance in Alzheimer’s disease models. This article interprets new exercise–muscle extracellular vesicle findings and translates them into more rigorous spatial, temporal, and mechanistic assay decisions.

• Amyloid Beta-Peptide (1-40): Translational Strategy

  2026-09-16

  A mechanistic and strategic framework for using Amyloid Beta-Peptide (1-40) (human) to connect calcium-sensitive membrane biology, amyloid assembly, neurotoxicity models, and translationally relevant experimental design.

• LY2886721: BACE1 Inhibition in AD Research

  2026-09-16

  LY2886721 is an oral BACE inhibitor with nanomolar activity in biochemical and cellular assays. Product data report amyloid beta reduction in HEK293Swe cells and PDAPP models, while peer-reviewed work defines a boundary between partial BACE1 inhibition and synaptic effects.

• Dual HER2–VEGFR2 Targeting in TNBC Research

  2026-09-15

  The reference study examines whether lapatinib and Telatinib can jointly suppress invasive and angiogenic phenotypes in the HER2-negative MDA-MB-231 triple-negative breast cancer model. Its main contribution is a mechanism-oriented preclinical framework that connects drug response with invadopodia formation, proliferation, and 2D angiogenesis rather than relying on viability alone.

513 records 1/35 page Next 12345 下5页 Last page